Insights
Search Results
Client Highlights
6.02.26
Wilson Sonsini Advises Contentful on Acquisition by Salesforce
On June 1, 2026, Salesforce, the world's No. 1 AI CRM, announced that it has signed a definitive agreement to acquire Contentful, a leading composable content platform trusted by over 4,800 of the world’s leading brands to deliver personalized digital experiences at scale. Wilson Sonsini Goodrich & Rosati advised Contentful on the transaction.
Client Highlights
4.29.26
Firm Advises Match Group on $100 Million Investment in Sniffies
On April 27, 2026, Match Group, a leading provider of digital technologies designed to help people make meaningful connections, announced a $100 million investment in Sniffies, a map-based platform serving non-heterosexual men. The investment represents a significant minority ownership stake and includes the option to acquire the remaining equity in the future. Sniffies will continue to operate independently and remain founder-led, with Match Group supporting the team's vision and growth. Wilson Sonsini Goodrich & Rosati advised Match Group on the transaction.
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
3.03.26
Wilson Sonsini Advises Versori on Acquisition by Avalara
On February 27, 2026, Avalara, the leading provider of cloud-based tax compliance automation software, announced that it acquired Versori Group, an integration platform company specializing in automated connector development powered by agentic AI. Wilson Sonsini Goodrich & Rosati advised Versori on the transaction.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
2.05.26
Wilson Sonsini Advises Fair Square Medicare on Acquisition by Senior Market Sales
On January 30, 2026, Senior Market Sales®(SMS), one of the industry’s premier insurance marketing organizations (IMOs), announced that it has acquired Fair Square Medicare, a technology-driven health care platform designed to simplify the Medicare experience for seniors. This strategic acquisition enhances SMS’ suite of digital tools and reinforces its commitment to providing guidance to seniors as they navigate Medicare coverage. Wilson Sonsini Goodrich & Rosati advised Fair Square on the transaction.
Client Highlights
2.03.26
Wilson Sonsini Advises Remote on Acquisition of Atlas
On January 20, 2026, Remote, the leading global employment operating system, announced it has completed its acquisition of Atlas, an AI-native expense management solution for global teams. The acquisition provides the foundation for a new category of products from Remote to enable customers to offer more holistic and modern employee experiences to their teams.
Client Highlights
1.23.26
Wilson Sonsini Advises Brex on $5.15 Billion Acquisition by Capital One
On January 22, 2026, Capital One announced that it has entered into a definitive agreement to acquire Brex, in a combination of stock and cash transaction valued at $5.15 billion. Brex is a modern, AI-native software platform offering intelligent finance solutions that make it easy for businesses to issue corporate cards, automate expense management, and make secure, real-time payments. The transaction is expected to close in the middle of 2026, subject to customary closing conditions. Wilson Sonsini Goodrich & Rosati advised Brex on the transaction.
Client Highlights
1.14.26
Wilson Sonsini Advises Polygon Labs on Acquisitions of Coinme and Sequence
On January 13, 2026, Polygon Labs announced definitive agreements to acquire Coinme and Sequence for more than $250 million to expand into regulated stablecoin payments in the U.S. Both companies will play foundational roles in building Polygon's forthcoming Open Money Stack, which aims to facilitate instant and reliable money movement. The Polygon Open Money Stack includes physical cash and digital fiat on- and off-ramps, wallet infrastructure, and cross-chain orchestration through intents. Wilson Sonsini Goodrich & Rosati is advising Polygon on both transactions.
Client Highlights
1.08.26
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.